DRD2: A Drug Target / Disease Biomarker (G1813)

Target Name: DRD2

NCBI ID: G1813

DRD2

DRD2: A Drug Target / Disease Biomarker

DRD2, short for dopamine receptor subtype 2, is a protein that is expressed in the brain and plays a crucial role in the neurotransmitter system. It is a target for many drugs, including antidepressants, and has been identified as a potential drug target for treating various psychiatric and neurological disorders.

DRD2 is a transmembrane protein that is composed of four transmembrane domains and an extracellular loop. It is expressed in the brain and is involved in the development and maintenance of neural circuits. It is a type I transmembrane protein, which means that it spans the entire thickness of the cell membrane and is involved in many different functions.

DRD2 is involved in the neurotransmitter system by interacting with dopamine, a neurotransmitter that plays a crucial role in the brain. It is known that DRD2 is a receptor for dopamine and that it is involved in the transduction of dopamine signals from the brain to the rest of the body.

DRD2 has been shown to be involved in a wide range of neural functions, including the modulation of neural circuits, the regulation of movement, and the control of behavioral state. It is also involved in the development and maintenance of neural plasticity, which is the ability of the brain to change and adapt over time.

One of the most promising aspects of DRD2 is its potential as a drug target. Many drugs that are used to treat psychiatric and neurological disorders are designed to interact with DRD2 and to modulate its activity. For example, antidepressants are known to work by modulating the activity of DRD2, and many other drugs that are used to treat anxiety and depression are also designed to interact with this protein.

DRD2 is also a potential biomarker for certain psychiatric and neurological disorders. The levels of DRD2 have been shown to be abnormal in individuals with certain psychiatric and neurological disorders, and may be used as a diagnostic marker for these conditions. For example, individuals with major depressive disorder (MDD) have been shown to have lower levels of DRD2 compared to healthy individuals.

In addition to its potential as a drug target and biomarker, DRD2 is also of interest to researchers because of its unique structure and its involvement in the neurotransmission. Many researchers are interested in understanding how DRD2 functions and how it can be targeted by drugs.

Overall, DRD2 is a protein that is of great interest to researchers because of its involvement in the neurotransmission and its potential as a drug target and biomarker. Further research is needed to fully understand its functions and its potential as a therapeutic agent.

Protein Name: Dopamine Receptor D2

Functions: Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (PubMed:21645528). Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

The "DRD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DRD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets